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The ongoing COVID-19 pandemic has impacted all fields of scientific research. Rheumatology, as a rapidly devel-
oping clinical discipline, has embraced positive trends in online research and offered some valuable survey data. 
Depending on target populations, their size, and geographic coverage, the obtained survey data may form a basis 
for rheumatology practice guidelines.
The validity of online surveys is subjected to employing reliable channels for questionnaire dissemination and 
timeline of collecting responses. The strengths and limitations of online surveys share similarities with those of 
other observational studies. The reliability of the data change over time, necessitating revised surveys. Although 
full ethics review is not mandatory for most surveys, some precautions are warranted to preserve the anonymity 
of surveyees and avoid unjustified promotion of (repurposed) drugs amidst the COVID-19 pandemic.
The EQUATOR Network endorsed the CHERRIES standard for online surveys. We have proposed a set of recom-
mendations that concentrate on designing questions, validating questionnaires, disseminating questionnaires via 
social media, choosing advanced platforms for data processing, and targeting journals. Given the relatively low 
citations of surveys, most high-impact journals decline related submissions outright. Nonetheless, some influen-
tial surveys, particularly those on COVID-19 vaccines for rheumatic patients, have been successfully published 
by top rheumatology journals.
During the ongoing pandemic, several other types of online research have gained their momentum. Bibliometric 
and altmetric analyses of COVID-19 publications, including those in rheumatology, have revealed trends suc-
cessful use of Twitter and Mendeley platforms for disseminating reliable information and ranking the most influ-
ential topics. It is expected that more and more clinicians will embrace the benefits of online research for their 
daily practice.
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AddITIOnAl hETErOlOgOuS VErSuS hOmOlOgOuS bOOSTEr 
VACCInATIOn In ImmunOSupprESSEd pATIEnTS wIThOuT SArS-COV-2 
AnTIbOdy SErOCOnVErSIOn AfTEr prImAry mrnA VACCInATIOn:  
A rAndOmIzEd COnTrOllEd TrIAl
dodatno heterologno Cijepljenje U odnosU na hoMologno 
pojačano Cijepljenje U iMUnosUpriMiranih paCijenata  
bez serokonverzije antitijela sars-Cov-2 nakon priMarnog 
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Objectives. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-induced coronavirus disease 2019 
(COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inade-
quately respond to conventional COVID-19 vaccination.
Methods. In this blinded randomized clinical trial we compare the efficacy and safety of an additional booster vac-
cination with a vector versus mRNA vaccine in non-seroconverted patients. We assigned 60 patients under ritux-
imab treatment, who did not seroconvert after their primary mRNA vaccination with either BNT162b2 (Pfizer–
BioNTech) or mRNA-1273 (Moderna), to receive a third dose, either using the same mRNA or the vector vaccine 
ChAdOx1 nCoV-19 (Oxford-AstraZeneca). Patients were stratified according to the presence of peripheral B-cells. 
The primary efficacy endpoint was the difference in the SARS-CoV-2 antibody seroconversion rate between vector 
(heterologous) and mRNA (homologous) vaccinated patients by week four. Key secondary endpoints included the 
overall seroconversion and cellular immune response; safety was assessed at weeks one and four.
Results. Seroconversion rates at week four were comparable between vector (6/27 patients, 22%) and mRNA 
(9/28, 32%) vaccine (p=0.6). Overall, 27% of patients seroconverted; specific T-cell responses were observed in 
20/20 (100%) vector versus 13/16 (81%) mRNA vaccinated patients. Newly induced humoral and/or cellular 
responses occurred in 9/11 (82%) patients. No serious adverse events, related to immunization, were observed.
Conclusions. This enhanced humoral and/or cellular immune response supports an additional booster vaccina-
tion in non-seroconverted patients irrespective of a heterologous or homologous vaccination regimen.
Trial registration: EudraCT 2021-002348-57
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hOw wE AdApTEd Our wOrK durIng ThE pAndEmIC.  
wErE wE SuCCESSful?
kako sMo prilagodili svoj rad tijekoM pandeMije.  
jesMo li bili Uspješni?
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COnTrOVErSIES In ThE TrETAmEnT Of COVId-19 pATIEnTS
kontroverze U zbrinjavanjU i liječenjU Covid-19 bolesnika
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Since we started to treat first COVID-19 patients and find out the gloomy perspectives of positive outcome, there 
was a desperate desire to improve survival by introducing new, “logical“ treatment options beside oxygenation, 
following the rapid elucidation of the pathogenesis of the disease. An intriguing option appeared that beside tar-
geting SARS-CoV-2, modulation of devastating inflammatory response and supression of extensive coagulation 
might increase survival rates. Severe COVID-19 is usually bilateral pneumonia with characteristics of ARDS, 
multiorgan dysfunction and disseminated intravascular coagulation. These are characteristics of sepsis. The same 
pattern of thinking developed as over thirty years ago. The idea was that survival might be increased with early 
pathogen oriented therapy (remdesivir), neutralization of viral S antigen with monoclonal antibodies (bamla-
nivimab, etesevimab, casirivimab/imdevimab), supression of inflamation with steroids (dexamethasone), supres-
sion of the production and neutralisation of activity of proinlflammatory cytokines IL-6 (toculizumab, sari-
lumab), IL-1 (anakinra), janus kinase (baricitinib, tofacitinib). Heparin and 5NOK inhibitors were used to supress 
and threat thrombosis. Unfortunately, in nineties we needed more than ten years to admit that only targeted 
antibacterial therapy, fluids, sympatomymetics, and in a selected group of patients hydrocortisone are of clinical 
importnace, while other antiinflamamtory therapeutic approaches were only the futile attemps. In Covid-19 pan-
demic that became clear after only one year due to the huge number of patients.
Our capabilities to supress viral replication by antiviral drugs (remdesivir) are still poor performing. Dexametha-
sone (6 mg daily) improve outcome in patients who need oxygen. Prophylactic heparin doses are as effective as 
therapeutic, and 5NOK inhibitors might be useful in very selected group of patients with proven extensive throm-
boses. Other therapeutic approaches are of little clinical significance. Intensive oxygen supplementation is needed. 
High-flow oxygenation became a standard therapy, but the outcome of mechanically ventilated patients is 
extremly poor, particularly in elderly. Early ECMO therapy is very useful but limited with low number of experi-
enced and well equiped centers. Since pandemics continue these facts should be considered to prevent doing 
harm instead of helping severly ill patients.
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